International perspective on physician knowledge, attitude and practices related to medical cannabis.
International perspective on physician knowledge, attitude and practices related to medical cannabis.
复制标题
关于医用大麻相关医生知识、态度和实践的国际视角。
DOI：
10.1101/2023.07.26.23293157
复制
发表时间：
2023
期刊：
影响因子：
--
通讯作者：
Radhakrishnan,Rajiv
中科院分区：
文献类型：
--
作者：
Syed,SharifulA;Singh,Jatinder;Elkholy,Hussien;Palavra,IrenaRojnic;Tomicevic,Marko;Eric,AnamarijaPetek;daCosta,MarianaPinto;Guloksuz,Sinan;Radhakrishnan,Rajiv
背景大麻的娱乐性使用和大麻用于医学适应症（即，“医用大麻”）近年来有所增长。尽管如此，指导临床决策的科学证据仍然有限，目前大麻医疗用途的证据强度被认为很低。与此相反，越来越多的证据表明，使用大麻会对健康产生负面影响。在这一迅速变化的环境中，医生对大麻治疗价值的态度变得至关重要。这项研究的目的是表征知识/经验，态度，和潜在的预测临床实践的医用cannabs.MethodsWe之间进行了一项横断面调查，从17个国家的医生2016年和2018年。该调查包括旨在探索医生关于使用医用大麻的知识，态度和做法的问题。描述性统计被用来检查愿意推荐医用大麻的医疗和精神适应症，然后通过回归分析，以确定医生愿意推荐医用cannabs.ResultsA的预测因素，共有323名医生回答了调查，其中53%是女性。平均年龄为35.4 ± 9.5岁，临床经验为10.04 ± 8.6年。医用大麻的临床经验总体有限（51.4%的人指出从未推荐过医用大麻，33%的人指出对医用大麻的了解不足）。大多数受访者（84%）认识到使用大麻的精神病风险，而只有23%的人正确识别了每日使用大麻成瘾的风险。总体而言，推荐医用大麻治疗化疗引起的恶心（67%）、难治性慢性神经性疼痛（52%）和肌萎缩侧索硬化症（ALS; 51%）痉挛的意愿最高。结论这项国际研究检查了医生的知识、态度和与医用大麻相关的实践，发现与医用大麻相关的特定领域知识存在显着差距。在推荐医用大麻的意愿方面存在很大的差异，这与目前的证据强度不一致。因此，这项研究强调需要加强与医用大麻领域特定知识相关的教育。
BackgroundThe trends of recreational use of cannabis and the use of cannabis for medical indications (i.e., “medical cannabis”) have grown in recent years. Despite that, there is still limited scientific evidence to guide clinical decision-making, and the strength of evidence for the medical use of cannabis is currently considered to be low. In contrast, there is growing evidence of negative health outcomes related to the use of cannabis. In this rapidly shifting landscape, the role of physician attitudes regarding the therapeutic value of cannabis has become essential. This study aimed to characterize knowledge/experience, attitudes, and potential predictors of clinical practice regarding medical cannabis.MethodsWe conducted a cross-sectional survey of physicians from 17 countries between 2016 and 2018. The survey consisted of questions designed to explore physician knowledge, attitude, and practices regarding the use of medical cannabis. Descriptive statistics were used to examine willingness to recommend medical cannabis for medical and psychiatric indications, followed by regression analysis to identify the predictors of physician willingness to recommend medical cannabis.ResultsA total of 323 physicians responded to the survey, among which 53% were women. The mean age was 35.4 ± 9.5 years, with 10.04 ± 8.6 years of clinical experience. Clinical experience with medical cannabis was overall limited (51.4% noted never having recommended medical cannabis and 33% noted inadequate knowledge regarding medical cannabis). The majority of respondents (84%) recognized the risk of psychosis with cannabis use, while only 23% correctly identified the risk of addiction with daily cannabis use. Overall, willingness to recommend medical cannabis was the highest for chemotherapy-induced nausea (67%), refractory chronic neuropathic pain (52%), and spasticity in amyotrophic lateral sclerosis (ALS; 51%).ConclusionThis international study examining physician knowledge, attitudes, and practices related to medical cannabis revealed that there are significant gaps in domain-specific knowledge related to medical cannabis. There is a wide variability in willingness to recommend medical cannabis, which is not consistent with the current strength of evidence. This study thus highlights the need for greater education related to domain-specific knowledge about medical cannabis.